RecruitingPhase 4NCT06831370
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Studying Classic Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Intervention
- Brentuximab Vedotin(drug)
- Enrollment
- 124 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (11)
- HCG City Cancer Centre, Vijayawada, Andhra Pradesh, India
- Gauhati Medical college and Hospital, Guwahati, Assam, India
- Unique Hospital Multispeciality and Research Institute, Surat, Gujarat, India
- HCG Cancer Centre, Bangalore, Karnataka, India
- JIPMER, Puducherry, Kerala, India
- HCG Manavata Cancer Centre, Nashik, Maharashtra, India
- ACTREC, Navi Mumbai, Maharashtra, India
- DMH, Pune, Maharashtra, India
- Rajiv Gandhi Cancer Hospital, Delhi, New Delhi, India
- NRS Medical college & Hospital, Kolkata, Kolkata, West Bengal, India
- AIIMS, New Delhi, India
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06831370 on ClinicalTrials.govOther trials for Classic Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07275216Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center
- RECRUITINGPHASE2NCT07209059PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaNational Research Center for Hematology, Russia
- RECRUITINGPHASE2NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaNational Medical Research Radiological Centre of the Ministry of Health of Russia
- RECRUITINGPHASE2NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE1, PHASE2NCT06642792A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaAkeso
- RECRUITINGPHASE2NCT06377540MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07234487Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTSt. Petersburg State Pavlov Medical University